{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:28:03Z","timestamp":1763202483930,"version":"3.37.3"},"reference-count":26,"publisher":"XMLink","issue":"1","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Basic Science Research Program","award":["2019R1C1C1006611"],"award-info":[{"award-number":["2019R1C1C1006611"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Hypertens"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There have been concerns regarding the safety of renin-angiotensin-aldosterone-system (RAAS)-blocking agents including angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) during the coronavirus disease 2019 (COVID-19) pandemic. This study sought to evaluate the impact of hypertension and the use of ACEI\/ARB on clinical severity in patients with COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 3,788 patients aged 30 years or older who were confirmed with COVID-19 with real time reverse transcription polymerase chain reaction were identified from a claims-based cohort in Korea. The primary study outcome was severe clinical events, a composite of intensive care unit admission, need for ventilator care, and death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients with hypertension (n\u2009=\u20091,190, 31.4\u2009%) were older and had higher prevalence of comorbidities than those without hypertension. The risk of the primary study outcome was significantly higher in the hypertension group, even after multivariable adjustment (adjusted odds ratio [aOR], 1.67; 95\u2009% confidence interval [CI], 1.04 to 2.69). Among 1,044 patients with hypertensive medical treatment, 782 (74.9\u2009%) were on ACEI or ARB. The ACEI\/ARB subgroup had a lower risk of severe clinical outcomes compared to the no ACEI\/ARB group, but this did not remain significant after multivariable adjustment (aOR, 0.68; 95\u2009% CI, 0.41 to 1.15).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with hypertension had worse COVID-19 outcomes than those without hypertension, while the use of RAAS-blocking agents was not associated with increased risk of any adverse study outcomes. The use of ACE inhibitors or ARBs did not increase the risk of adverse COVID-19 outcomes, supporting current guidance to continue these medications when indicated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40885-021-00168-0","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:03:31Z","timestamp":1622505811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19"],"prefix":"10.5646","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4755-6367","authenticated-orcid":false,"given":"Si-Hyuck","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-2569","authenticated-orcid":false,"given":"Dong-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6096-1263","authenticated-orcid":false,"given":"Kyung-Do","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-8777","authenticated-orcid":false,"given":"Jin-Hyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0612-2562","authenticated-orcid":false,"given":"Sang-Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7112-8277","authenticated-orcid":false,"given":"Andrew M.","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5887-8348","authenticated-orcid":false,"given":"Henry G.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-4442","authenticated-orcid":false,"given":"Tae-Jin","family":"Youn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Ho","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18617","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"168_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727\u201333.","journal-title":"N Engl J Med"},{"key":"168_CR2","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708\u201320.","journal-title":"N Engl J Med"},{"key":"168_CR3","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260\u20133.","journal-title":"Science"},{"key":"168_CR4","doi-asserted-by":"publisher","first-page":"e00127-20","DOI":"10.1128\/JVI.00127-20","volume":"9","author":"Y Wan","year":"2020","unstructured":"Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;9:e00127-20.","journal-title":"J Virol"},{"key":"168_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281\u201392.e6.","journal-title":"Cell"},{"key":"168_CR6","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605\u201310.","journal-title":"Circulation"},{"key":"168_CR7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","volume":"43","author":"Y Ishiyama","year":"2004","unstructured":"Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970\u20136.","journal-title":"Hypertension"},{"key":"168_CR8","unstructured":"European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed date: May 2020."},{"key":"168_CR9","unstructured":"American College of Cardiology. HFSA\/ACC\/AHA Statement addresses concerns re: using RAAS antagonists in COVID-19. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/03\/17\/08\/59\/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. Accessed date: May 2020."},{"key":"168_CR10","doi-asserted-by":"crossref","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127-248.","DOI":"10.1161\/HYP.0000000000000076"},{"key":"168_CR11","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1093\/eurheartj\/ehz681","volume":"40","author":"T McCormack","year":"2019","unstructured":"McCormack T, Boffa RJ, Jones NR, Carville S, McManus RJ. The 2018 ESC\/ESH hypertension guideline and the 2019 NICE hypertension guideline, how and why they differ. Eur Heart J. 2019;40:3456\u20138.","journal-title":"Eur Heart J"},{"key":"168_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40885-019-0124-x","volume":"25","author":"HY Lee","year":"2019","unstructured":"Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, et al. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;25:20.","journal-title":"Clin Hypertens"},{"key":"168_CR13","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653\u20139.","journal-title":"N Engl J Med"},{"key":"168_CR14","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431\u201340.","journal-title":"N Engl J Med"},{"key":"168_CR15","unstructured":"#opendata4covid19. https:\/\/www.ohdsi.org\/wp-content\/uploads\/2020\/12\/Chan-PPT.pdf. Accessed Apr 16, 2020."},{"key":"168_CR16","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1038\/s41598-019-46965-4","volume":"9","author":"SH Kang","year":"2019","unstructured":"Kang SH, Kim SH, Cho JH, Yoon CH, Hwang SS, Lee HY, et al. Prevalence, awareness, treatment, and control of hypertension in Korea. Sci Rep. 2019;9:10970.","journal-title":"Sci Rep"},{"key":"168_CR17","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1093\/eurheartj\/ehz564","volume":"40","author":"SW Jeong","year":"2019","unstructured":"Jeong SW, Kim SH, Kang SH, Kim HJ, Yoon CH, Youn TJ, et al. Mortality reduction with physical activity in patients with and without cardiovascular disease. Eur Heart J. 2019;40:3547\u201355.","journal-title":"Eur Heart J"},{"key":"168_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","volume":"5","author":"J Li","year":"2020","unstructured":"Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5:825\u201330.","journal-title":"JAMA Cardiol"},{"key":"168_CR19","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671\u201381.","journal-title":"Circ Res"},{"key":"168_CR20","doi-asserted-by":"publisher","first-page":"e017364","DOI":"10.1161\/JAHA.120.017364","volume":"9","author":"A Palazzuoli","year":"2020","unstructured":"Palazzuoli A, Mancone M, De Ferrari GM, Forleo G, Secco GG, Ruocco GM, et al. Antecedent administration of angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists and survival after hospitalization for COVID-19 syndrome. J Am Heart Assoc. 2020;9:e017364.","journal-title":"J Am Heart Assoc"},{"key":"168_CR21","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362.","journal-title":"Lancet"},{"key":"168_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40885-018-0098-0","volume":"24","author":"HC Kim","year":"2018","unstructured":"Korean Society Hypertension (KSH), Hypertension Epidemiology Research Working Group. Kim HC, Cho MC. Korea hypertension fact sheet 2018. Clin Hypertens. 2018;24:13.","journal-title":"Clin Hypertens"},{"key":"168_CR23","doi-asserted-by":"publisher","first-page":"e019669","DOI":"10.1161\/JAHA.120.019669","volume":"10","author":"J An","year":"2021","unstructured":"An J, Wei R, Zhou H, Luong TQ, Gould MK, Mefford MT, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use and COVID-19 infection among 824 650 patients with hypertension from a US integrated healthcare system. J Am Heart Assoc. 2021;10:e019669.","journal-title":"J Am Heart Assoc"},{"key":"168_CR24","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2589-7500(20)30289-2","volume":"3","author":"DR Morales","year":"2021","unstructured":"Morales DR, Conover MM, You SC, Pratt N, Kostka K, Duarte-Salles T, et al. Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. Lancet Digit Health. 2021;3:e98\u2013114.","journal-title":"Lancet Digit Health"},{"key":"168_CR25","doi-asserted-by":"publisher","unstructured":"Zastrow M. South Korea is reporting intimate details of COVID-19 cases: has it helped? Nature. 2020. https:\/\/doi.org\/10.1038\/d41586-020-00740-y.","DOI":"10.1038\/d41586-020-00740-y"},{"key":"168_CR26","unstructured":"Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995;40:141\u20134."}],"container-title":["Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40885-021-00168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40885-021-00168-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40885-021-00168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T16:39:10Z","timestamp":1736181550000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalhypertension.biomedcentral.com\/articles\/10.1186\/s40885-021-00168-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["168"],"URL":"https:\/\/doi.org\/10.1186\/s40885-021-00168-0","relation":{},"ISSN":["2056-5909"],"issn-type":[{"type":"electronic","value":"2056-5909"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"11 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was exempt from review by the Seoul National University Bundang Hospital Institutional Review Board (IRB No: X-2005-611-902). It complied with the requirements of the 2013 Declaration of Helsinki, and the need for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No individual data in any form is disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SHK is a visiting scholar at Google. AMD and HGW are employees of Google Health. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}